Form 8-K - Current report:
SEC Accession No. 0001493152-24-047928
Filing Date
2024-11-27
Accepted
2024-11-27 09:26:40
Documents
17
Period of Report
2024-11-21
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 2.03: Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant
Item 3.01: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 form8-k.htm   iXBRL 8-K 61822
2 ex4-1.htm EX-4.1 208245
3 ex10-1.htm EX-10.1 466450
4 ex10-2.htm EX-10.2 292348
  Complete submission text file 0001493152-24-047928.txt   1451077

Data Files

Seq Description Document Type Size
5 XBRL SCHEMA FILE bfri-20241121.xsd EX-101.SCH 3976
6 XBRL DEFINITION FILE bfri-20241121_def.xml EX-101.DEF 30397
7 XBRL LABEL FILE bfri-20241121_lab.xml EX-101.LAB 37210
8 XBRL PRESENTATION FILE bfri-20241121_pre.xml EX-101.PRE 27416
20 EXTRACTED XBRL INSTANCE DOCUMENT form8-k_htm.xml XML 6647
Mailing Address 120 PRESIDENTIAL WAY, SUITE 330 WOBURN MA 01801
Business Address 120 PRESIDENTIAL WAY, SUITE 330 WOBURN MA 01801 781-245-1325
Biofrontera Inc. (Filer) CIK: 0001858685 (see all company filings)

EIN.: 473765675 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-40943 | Film No.: 241506969
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)